This biotech name is evolving into a major obesity play. How to trade it with options
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
TL;DR
- Amgen is transitioning its focus to obesity, rare disease, and next-generation oncology to compensate for the decline of its Enbrel franchise.
- Early positive results from Imdelltra (lung cancer), the Horizon rare-disease portfolio, and the MariTide obesity program are bolstering investor confidence.
- The company's stock has broken through resistance levels and is outperforming the S&P 500, indicating renewed institutional interest.
- Amgen maintains strong fundamentals, including a competitive P/E ratio, healthy net margins, and significant free cash flow generation.
- Key growth drivers include the MariTide obesity therapy, the leverage from the Horizon acquisition (Tepezza and Krystexxa), successful oncology execution with Imdelltra, and a rapidly growing biosimilar portfolio.
- Potential risks include margin compression due to increased R&D expenses and the pace of legacy erosion from Enbrel.
- A defined-risk options strategy (Feb $330/$365 call vertical) is suggested for bullish investors.